Moreover, AML with myelodysplastic-related changes and therapy-related AML are associated with poor prognostic cytogenetic features, such as a complex karyotype and TP53 mutation, and are more frequent in the elderly; they show very unsatisfactory response rates to conventional IC, making it suitable neither for all patients nor for all diseases [2]. This evidence concerns the gene TP53 and acute myeloid leukemia.